ConductScience.org, home

Comparison · NCT05486416-sae

HSK3486 for General Anesthesia Induction vs Propofol for General Anesthesia Induction: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. HSK3486 for General Anesthesia Induction vs Propofol for General Anesthesia Induction: serious adverse events. Trial comparisons, record NCT05486416-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05486416-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01670.007140.0384wilson
Risk in group 20.00690.001220.038wilson
Risk difference, group 1 minus group 20.00977-0.02280.0322newcombe hybrid score
Risk ratio, group 1 over group 22.420.28520.5log
Odds ratio, group 1 over group 22.440.28321.1log
Number needed to harm, for one more participant with a serious adverse event on HSK3486 for General Anesthesia Induction than on Propofol for General Anesthesia Induction102from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1HSK3486 for General Anesthesia InductionHSK3486 for induction of general anesthesia~HSK3486: HSK3486 for induction of general anesthesia5300EG000
Group 2Propofol for General Anesthesia InductionPropofol for induction of general anesthesia~Propofol: Propofol for induction of general anesthesia1145EG001

Harm

What it counts
Total, serious adverse events
Time frame
AEs will be collected from the time of informed consent until the final study visit (Day 8). A treatment-emergent AE is defined as: an AE that occurs after the subject starts treatment with the IMP. If an Investigator becomes aware of a serious adverse event within 30 days after the last dose of study drug and it is considered by him/her to be caused by the study drug with a reasonable possibility, the event must be documented and reported.

Source ClinicalTrials.gov

Trial

Title
Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery
NCT number
NCT05486416
Phases
PHASE3
Conditions
General Anesthesia
Interventions
HSK3486, Propofol
Lead sponsor
Haisco-USA Pharmaceuticals, Inc.
Results first posted
2025-08-11

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05486416-sae